You have read all your free articles, to continue reading subscribe to read the rest of this content.
The Malmö based “micro-pharma” aiming at developing innovative new approaches to treat diabetes, PILA PHARMA has acquired XEN-D0501, a clinical ready and safe TRPV1 antagonist development candidate, previously owned by Ario Pharma. The acquired asset include a series of small molecule TAlready a subscriber Login You have read all your free articles, to continue reading…
Technomark Life Sciences and Promore Pharma announced earlier this summer a strategic collaboration on the end-stage development of PXL01 for European registration and marketing, a product opportunity for prevention of post-surgical adhesions after hand-surgery, which has completed Phase II trials. Already a subscriber Login You have read all your free…
The Board of Directors and Nomination Committee have proposed the appointment of Anna Ljung as the new CEO of Moberg Pharma, while current CEO Peter Wolpert will transition to a role as Executive Chairman of the Board of Directors. The divestment of the OTC business on March 29, 2019 represents…
Medivir announces that the independent Data Monitoring Committee (DMC) held its fourth and final scheduled meeting and recommended continuation of the ongoing randomized, double-blind phase IIa study (MIV-711-201) based on a review of unblinded safety data. The objective of MIV-711-201 is to evalAlready a subscriber Login You have read all…
